NKGen Biotech, Inc. Common Stock (NKGN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NKGen Biotech, Inc. Common Stock (NKGN) trades at $0.06 with AI Score 53/100 (Grade B). NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for neurodegenerative and oncological diseases. Market cap: $7.84M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for NKGN: NKGN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NKGN against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
NKGN: 2/7 perspectives are bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →NKGen Biotech, Inc. Common Stock (NKGN) Healthcare & Pipeline Overview
NKGen Biotech, Inc. is a pioneering clinical-stage biotechnology firm specializing in cell therapies for neurodegenerative and oncological diseases, utilizing activated natural killer (NK) cells to address critical health challenges in the U.S. market.
What Is the Investment Thesis for NKGN?
NKGen Biotech, Inc. presents a compelling investment thesis based on its unique focus on activated NK cell therapies, which are positioned to address significant unmet medical needs in neurodegenerative and oncological diseases. The company's lead product, SNK01, is in Phase I/IIa trials, with potential market entry in the next few years, targeting a growing demographic of patients with Alzheimer's and Parkinson's diseases. The global market for Alzheimer's disease treatment alone is projected to reach $12 billion by 2025, providing a substantial revenue opportunity. Additionally, the successful completion of Phase 1 trials for SNK02, aimed at refractory solid tumors, positions the company favorably within the oncology space. NKGen's strategic partnerships enhance its research capabilities and market reach, particularly in Japan, where regulatory pathways may facilitate quicker access to market. However, investors may want to evaluate the inherent risks associated with clinical-stage biotechnology firms, including regulatory hurdles and the need for successful trial outcomes.
Based on FMP financials and quantitative analysis
NKGN Key Highlights
- Market Cap of $7.84M, indicating a nascent stage in the biotechnology sector.
- Beta of 0.65, suggesting lower volatility compared to the broader market.
- No dividend yield, reflecting a focus on reinvestment in R&D rather than shareholder returns.
- 63 employees, indicating a lean operational structure typical of clinical-stage biotech firms.
- Strategic partnerships with HekaBio K.K. and NKMAX Co., Ltd. to bolster R&D and market access.
Who Are NKGN's Competitors?
NKGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | $61.78 | +2.83% | $5.96B | 44 |
| NVS Novartis AG | $155.20 | -2.94% | $296.14B | 57 |
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| ALNY Alnylam Pharmaceuticals, Inc. | $313.04 | +0.08% | $41.79B | 95 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NKGN's Key Strengths?
- Innovative approach utilizing activated NK cells for therapy development.
- Strong leadership team with experience in biotechnology and clinical development.
- Strategic partnerships enhancing R&D capabilities and market access.
- Focused pipeline targeting high unmet medical needs in neurodegenerative and oncological diseases.
What Are NKGN's Weaknesses?
- Limited financial resources typical of clinical-stage biotechnology companies.
- Dependence on successful clinical trial outcomes for product advancement.
- Potential challenges in navigating complex regulatory environments.
- Relatively small employee base may limit operational capacity.
What Could Drive NKGN Stock Higher?
- Completion of Phase I/IIa trials for SNK01, with results expected to drive market interest.
- Strategic partnership with HekaBio K.K. facilitating development and commercialization in Japan.
- Progression of SNK02 into later clinical trial phases, potentially expanding the product pipeline.
- Continuous research and development efforts aimed at enhancing NK cell therapy efficacy.
- Potential regulatory submissions for SNK01 and SNK02, which could unlock new market opportunities.
What Are the Key Risks for NKGN?
- Financial-distress signal — its Altman Z-Score of -15.71 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles could delay the approval process for NKGen's therapies.
- Dependence on successful clinical trial outcomes to advance product development.
- Market competition may impact the company's ability to capture market share.
- Financial constraints typical of clinical-stage biotech firms could limit operational capabilities.
What Are the Growth Opportunities for NKGN?
- Growth opportunity 1: The global market for Alzheimer's disease treatments is projected to reach $12 billion by 2025, driven by an aging population and increasing prevalence of the disease. NKGen's SNK01 therapy, targeting this market, could capture significant market share if clinical trials demonstrate efficacy and safety, positioning the company favorably for commercialization.
- Growth opportunity 2: The oncology market is rapidly evolving, with the global CAR-T cell therapy market expected to exceed $20 billion by 2025. NKGen's SNK02, an allogenic NK cell therapy, is well-positioned to capitalize on this trend, particularly as it targets refractory solid tumors, an area with high unmet medical needs.
- Growth opportunity 3: NKGen's strategic partnership with HekaBio K.K. opens avenues for market entry in Japan, a region known for its advanced healthcare infrastructure and supportive regulatory environment for innovative therapies. This partnership could accelerate the development and commercialization of NKGen's therapies in Asia, increasing its global footprint.
- Growth opportunity 4: The increasing focus on immunotherapy as a treatment modality in oncology presents a significant opportunity for NKGen. As more healthcare providers and patients seek effective treatments for cancer, NKGen's NK cell therapies could emerge as viable options, enhancing the company's market position.
- Growth opportunity 5: The rise in investment and interest in cell therapies, particularly those utilizing NK cells, is expected to drive funding and research opportunities. NKGen can leverage this trend to enhance its research capabilities and accelerate the development of its pipeline, potentially leading to new therapeutic candidates.
What Opportunities Does NKGN Have?
- Growing market demand for effective treatments in neurodegenerative diseases.
- Expansion into international markets through strategic partnerships.
- Increasing investment in cell and gene therapies within the biotechnology sector.
- Potential for new product development leveraging existing research.
What Threats Does NKGN Face?
- Intense competition from established biotechnology and pharmaceutical companies.
- Regulatory hurdles that could delay product approvals and market entry.
- Market volatility impacting funding and investment opportunities.
- Rapid technological advancements requiring continuous innovation.
What Are NKGN's Competitive Advantages?
- Innovative focus on activated NK cell therapies, differentiating from traditional treatment modalities.
- Strong strategic partnerships with established healthcare companies enhance credibility and market access.
- Proprietary technology and research capabilities in cell therapy development.
- Potential for first-mover advantage in specific therapeutic areas like neurodegenerative diseases.
What Does NKGN Do?
Founded in 2017 and headquartered in Santa Ana, California, NKGen Biotech, Inc. is a clinical-stage biotechnology company dedicated to advancing cell therapies for neurodegenerative and oncological diseases. The company's innovative approach centers around activated natural killer (NK) cells, which play a crucial role in the immune response against cancer and other diseases. NKGen's lead product, SNK01, is an autologous NK cell therapy currently undergoing Phase I/IIa trials aimed at treating neurodegenerative conditions such as Alzheimer's and Parkinson's diseases. Additionally, NKGen is advancing SNK02, an allogenic NK cell therapy that has successfully completed Phase 1 trials, alongside a HER2-CAR NK cell therapy candidate currently in pre-clinical development targeting refractory solid tumors. The company has established a strategic partnership with HekaBio K.K., a Japan-based healthcare platform, to facilitate the development, clinical trials, regulatory approvals, and commercialization of its autologous NK cell therapy products for central nervous system and autoimmune conditions in Japan. Furthermore, NKGen holds a license agreement with NKMAX Co., Ltd. for the research and development of its NK cell program, underscoring its commitment to innovation and collaboration in the biotechnology sector.
What Products and Services Does NKGN Offer?
- Develops autologous and allogenic NK cell therapies for neurodegenerative and oncological diseases.
- Conducts clinical trials to evaluate the safety and efficacy of its NK cell therapy candidates.
- Partners with other healthcare companies to enhance R&D and market access.
- Focuses on addressing unmet medical needs in Alzheimer's, Parkinson's, and cancer treatments.
- Utilizes activated natural killer cells to improve patient outcomes in various diseases.
- Engages in regulatory processes to obtain approvals for its therapies.
How Does NKGN Make Money?
- Generates revenue through the commercialization of successful cell therapies.
- Collaborates with strategic partners for research and development funding.
- Engages in licensing agreements to expand its therapeutic pipeline.
- Pursues grants and funding opportunities to support clinical trials.
- Focuses on gaining regulatory approvals to enhance marketability of its products.
What Industry Does NKGN Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment in research and development, particularly in the areas of cell and gene therapies. The global biotechnology market is expected to grow at a CAGR of approximately 7.4% from 2021 to 2028, driven by advancements in personalized medicine and immunotherapies. NKGen Biotech, Inc. operates within this dynamic landscape, focusing on cell therapies that utilize activated NK cells, a niche yet promising area with the potential to revolutionize treatment paradigms for neurodegenerative and oncological diseases. The competitive landscape includes various players focusing on similar therapeutic areas, emphasizing the need for NKGen to differentiate its offerings through clinical success and strategic partnerships.
Who Are NKGN's Key Customers?
- Patients suffering from neurodegenerative diseases such as Alzheimer's and Parkinson's.
- Oncology patients with refractory solid tumors seeking innovative treatment options.
- Healthcare providers and institutions looking for advanced therapies.
- Regulatory bodies for approvals and compliance.
- Collaborative partners in the healthcare and biotechnology sectors.
Company Profile
NKGen Biotech, Inc. Common Stock operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Santa Ana, US. The company is led by CEO Paul Y. Song. NKGN has traded publicly since 2023.
F-Score 3/9Financial Health
NKGen Biotech, Inc. Common Stock's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.71 places it in the distress zone, a signal of elevated financial risk.
ROE 56%Key Financial Metrics
Return on equity for NKGen Biotech, Inc. Common Stock stands at 55.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -88.8%, showing how much profit it generates from its asset base. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.
NKGN Valuation & Market Position
With a $7.84M market cap, NKGen Biotech, Inc. Common Stock sits in the micro-cap segment of the market. Relative to its peer group, NKGN's quantitative score of 53/100 is below the peer average of 73/100.
NKGN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in NKGen's upcoming clinical trials, which could validate their innovative therapies.
- Community sentiment has shifted positively, with increased discussions around the company's potential to address unmet medical needs.
- NKGen's partnerships with leading research institutions enhance credibility and may accelerate product development timelines.
- The biotech sector has seen renewed interest, with investors looking for promising candidates, positioning NKGen favorably.
Bear Case
- Concerns over regulatory hurdles loom large, as the biotech industry faces increased scrutiny from authorities.
- Social sentiment reflects caution, with some investors worried about the company's cash burn rate amidst ongoing trials.
- Market perception remains cautious, as past biotech failures weigh on investor confidence in similar stocks.
- Recent news reports highlight potential delays in trial results, causing uncertainty in the company's future prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NKGN Latest News
-
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer's Disease Program Across U.S. to Improve Patient Access and Support Enrollment
globenewswire.com · May 19, 2026
-
Why Barnes Group Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Friday's Mid-Day Session
benzinga · Oct 27, 2023
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Oct 3, 2023
NKGN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NKGN.
Price Targets
Wall Street price target analysis for NKGN.
NKGN MoonshotScore
What does this score mean?
The MoonshotScore rates NKGN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer's Disease Program Across U.S. to Improve Patient Access and Support Enrollment
Why Barnes Group Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Stocks That Hit 52-Week Lows On Tuesday
Leadership: Paul Y. Song
CEO
Paul Y. Song has extensive experience in the biotechnology sector, having held various leadership roles in clinical development and strategic planning. He holds a medical degree and has a strong background in oncology and immunotherapy, contributing to his expertise in advancing innovative therapies. His educational credentials include a degree from a prestigious medical school, and he has been involved in numerous successful biotech ventures.
Track Record: Under Paul Y. Song's leadership, NKGen Biotech has made significant strides in advancing its clinical pipeline, particularly with the development of its NK cell therapies. His strategic vision has led to key partnerships that enhance the company's research capabilities and market potential.
NKGN OTC Market Information
NKGen Biotech, Inc. trades on the OTC Other tier, which generally includes companies that do not meet the requirements for listing on major exchanges like NYSE or NASDAQ. This tier may have less stringent reporting requirements, but it also often indicates lower liquidity and higher volatility compared to listed stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial resources typical of OTC companies may impact operational capabilities.
- Lower visibility and investor interest compared to companies listed on major exchanges.
- Potential for higher volatility due to lower trading volumes.
- Regulatory risks associated with clinical-stage biotechnology firms.
- Verify the company's clinical trial progress and results.
- Assess the strength and terms of strategic partnerships.
- Review financial health and funding sources.
- Investigate the management team's track record and experience.
- Examine the competitive landscape and market positioning.
- Established partnerships with recognized entities in the healthcare sector.
- Presence of experienced leadership with a strong background in biotechnology.
- Ongoing clinical trials demonstrating commitment to R&D.
NKGN Healthcare Stock FAQ
What does NKGen Biotech, Inc. Common Stock do?
NKGen Biotech, Inc. is focused on developing innovative cell therapies utilizing activated natural killer (NK) cells to treat neurodegenerative and oncological diseases. The company is advancing several product candidates, including SNK01 for Alzheimer's and Parkinson's diseases, and SNK02 for refractory solid tumors, through various stages of clinical trials.
What are the main risks for NKGN?
The primary risks associated with NKGen Biotech, Inc. include regulatory hurdles that may delay product approvals, dependence on successful clinical trial outcomes, and intense competition from established biotechnology firms. Additionally, financial constraints typical of clinical-stage companies may limit operational capabilities and research funding.
How does NKGen Biotech, Inc. navigate regulatory approval processes?
NKGen Biotech, Inc. engages in a comprehensive regulatory strategy to navigate the approval processes for its therapies. This includes conducting rigorous clinical trials to demonstrate safety and efficacy, maintaining compliance with FDA guidelines, and collaborating with regulatory bodies to ensure timely submissions. The company's leadership team has experience in managing regulatory pathways, which is crucial for advancing its innovative NK cell therapies.
What are the key factors to evaluate for NKGN?
NKGen Biotech, Inc. Common Stock (NKGN) holds an AI score of 53/100 (moderate). Not financial advice.
How frequently does NKGN data refresh on this page?
NKGN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NKGN's recent stock price performance?
NKGen Biotech, Inc. Common Stock (NKGN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative approach utilizing activated NK cells for therapy development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NKGN overvalued or undervalued right now?
Valuing NKGen Biotech, Inc. Common Stock (NKGN) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NKGN?
Before investing in NKGen Biotech, Inc. Common Stock (NKGN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The company operates in a highly regulated industry with associated risks.